Skip to content
drillr.ai
Sign up

AZN.CA

AstraZeneca PLC

Healthcare · Drug Manufacturers - General · GB

Also listed · AZN →AZNVD →AZNVF →MILE.CA →OJO.CA →
—
Ask drillr

  • Oct 30, 2026, 07:38 UTC

    ASTRAZENECA PLC reported third-quarter net profit of $3.12 billion, up from $2.535 billion a year earlier, on strong cancer-drug sales.

    Source:

  • Oct 30, 2026, 07:12 UTC

    ASTRAZENECA PLC reported that third-quarter revenue rose 7%, driven by growth in its oncology business.

    Source:

  • Oct 30, 2026, 07:02 UTC

    ASTRAZENECA PLC reported third-quarter core earnings per share of $2.79, above expectations of $2.62.

    Source:

  • Oct 29, 2026, 15:02 UTC

    VEEVA SYSTEMS INC announced that executives from ASTRAZENECA PLC, BRISTOL MYERS SQUIBB CO, Grünenthal GmbH, NOVO NORDISK A S, Roche Holdings, Inc. and UCB SA are among those featured at Veeva Summit, which presents innovations in AI and data for an agent-based commercial model.

    Source:

  • Oct 28, 2026, 12:00 UTC

    ASTRAZENECA PLC announced the launch of the Meet Your Mark public health campaign to raise awareness of cancer biomarker testing.

    Source:

  • Oct 28, 2026, 04:32 UTC

    ASTRAZENECA PLC presented positive full-analysis data for sone-ve in the CLARITY-Gastric01 trial at ESMO 2026 on October 27.

    Source:

  • Oct 26, 2026, 08:49 UTC

    HUTCHMED (China) Ltd. announced positive Phase III SANOVO results showing that savolitinib plus osimertinib reduced the risk of disease progression or death by 44% overall and 55% among patients with high MET overexpression, compared with osimertinib alone.

    Source:

  • Oct 25, 2026, 15:30 UTC

    ASTRAZENECA PLC reported positive Phase III SAFFRON trial results showing TAGRISSO (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% versus platinum-based chemotherapy in patients with MET-driven EGFR-mutated non-small cell lung cancer after progression on TAGRISSO.

    Source:

  • Oct 24, 2026, 14:30 UTC

    ASTRAZENECA PLC reported positive Phase III VOLGA trial results, with perioperative IMFINZI plus neoadjuvant enfortumab vedotin reducing the risk of recurrence by 49% and the risk of death by 42% versus standard of care in patients with muscle-invasive bladder cancer.

    Source:

  • Oct 24, 2026, 10:45 UTC

    ASTRAZENECA PLC said it would make sunvozertinib commercially available in the United States under the brand name Zegfrovy.

    Source:

  • Oct 22, 2026, 07:12 UTC

    China approved Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as a conditional single-agent treatment for adults with unresectable or metastatic HER2 IHC 3+ solid tumors who have received prior treatment or have no satisfactory alternative.

    Source:

  • Oct 22, 2026, 07:01 UTC

    Abu Dhabi Biobank and ASTRAZENECA PLC partnered to advance predictive healthcare.

    Source:

  • Oct 21, 2026, 23:06 UTC

    The U.S. Food and Drug Administration approved an ASTRAZENECA PLC drug for a rare kidney disease in adults.

    Source:

  • Oct 21, 2026, 09:15 UTC

    UK-listed shares had mixed moves, with Ithaca Energy PLC/ADR, Computacenter Plc, Scottish Mortgage Investment Trust Plc, BP, Lion Finance Group Plc and Polar Capital Technology Trust Plc rising, while 3i Group Plc, NEXT GROUP PLC, London Stock Exchange Group Plc, UNILEVER PLC, ASTRAZENECA PLC and Fresnillo Plc fell.

    Source:

  • Oct 20, 2026, 13:00 UTC

    AMGEN INC and ASTRAZENECA PLC announced full Phase 3 CROSSING trial results showing that TEZSPIRE improved co-primary and key secondary endpoints in adolescent and adult patients with eosinophilic esophagitis, with symptom improvements at week 24 sustained through week 52.

    Source:

  • Oct 20, 2026, 07:45 UTC

    ASTRAZENECA PLC and ORACLE CORP announced a global collaboration to apply AI, real-world data and clinical capabilities to clinical research and care, with an initial hypertension-care and clinical-research programme in Abu Dhabi in partnership with M42 Ltd..

    Source:

  • Oct 20, 2026, 03:56 UTC

    ORACLE CORP and ASTRAZENECA PLC announced a non-binding agreement to explore AI and real-world data applications in clinical research and care.

    Source:

  • Oct 19, 2026, 11:00 UTC

    ASTRAZENECA PLC announced that it will present more than 100 abstracts, including results from five pivotal Phase III trials and four Presidential Symposium presentations, at the ESMO Congress on October 23–27, 2026.

    Source:

  • Oct 15, 2026, 23:15 UTC

    ASTRAZENECA PLC shares closed at $166.68, up 2.87% from the previous trading session.

    Source:

  • Oct 15, 2026, 23:00 UTC

    ASTRAZENECA PLC and Insitro, Inc. signed a multi-year AI drug-discovery partnership focused on potential treatments for MASH and cardiomyopathies.

    Source:

  • Oct 15, 2026, 16:15 UTC

    The UNIVERSITY OF LIVERPOOL’s Bengaluru campus enrolled nearly 300 undergraduate and postgraduate students in its inaugural cohort across six programmes.

    Source:

  • Oct 12, 2026, 23:18 UTC

    China’s Center for Drug Evaluation proposed priority review for a new indication of ASTRAZENECA PLC’s rilzabrutinib injection to reduce proteinuria in adults with primary IgA nephropathy.

    Source:

  • Oct 11, 2026, 18:45 UTC

    ASTRAZENECA PLC committed $1 billion to expand in Massachusetts.

    Source:

  • Oct 8, 2026, 10:30 UTC

    Kazakhstan's SK-Pharmacy signed a long-term supply contract with ASTRAZENECA PLC.

    Source:

  • Oct 8, 2026, 09:15 UTC

    Imperial Brands, Inc. shares rose 3.30% to 2,570.00p, leading the FTSE 100 gainers, while other named shares also advanced or declined.

    Source:

  • Oct 8, 2026, 08:44 UTC

    China's National Medical Products Administration approved ASTRAZENECA PLC and Daiichi Sankyo's Datroway for adults with unresectable or metastatic triple-negative breast cancer who are unsuitable for PD-1/PD-L1 inhibitor treatment.

    Source:

  • Oct 6, 2026, 23:15 UTC

    ASTRAZENECA PLC shares closed at $158.61, up 1.33% from the previous trading day.

    Source:

  • Oct 6, 2026, 10:15 UTC

    AstraZeneca opened a major research and development center in Cambridge, comprising 10 floors of interconnecting workspaces over 570,000 square feet.

    Source:

  • Oct 5, 2026, 16:03 UTC

    AstraZeneca opened a new global strategic R&D center in Kendall Square, Cambridge, Massachusetts, investing $1 billion and expanding its Massachusetts workforce by more than 50%.

    Source:

  • Sep 29, 2026, 23:16 UTC

    AstraZeneca (AZN) shares closed at $164.21, down 1.17% from the prior trading session.

    Source:

  • Sep 29, 2026, 00:18 UTC

    AstraZeneca filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer, as disclosed by HUTCHMED.

    Source:

  • Aug 24, 2026, 12:30 UTC

    The FTSE 100 rose 13 points to 10,830 by midday on 24 August 2026, led by miners and travel stocks, while the FTSE 250 slipped 0.1% to 24,703.

    Source:
Page 1Next →